Obesity Clinical Trial
Official title:
The HARMONY Study: A Culturally-relevant, Randomized-controlled, Stress Management Intervention to Reduce Cardiometabolic Risk in African American Women
Verified date | January 2024 |
Source | University of North Carolina, Chapel Hill |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will test whether a culturally-tailored nutrition and exercise intervention designed for African-American women will lead to sustained improvements in exercise and healthy eating through improvements in self-management mediators: mindfulness, stress management, positive reappraisal, self-regulation, and self-efficacy.
Status | Active, not recruiting |
Enrollment | 174 |
Est. completion date | February 18, 2025 |
Est. primary completion date | February 18, 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Self-reported African American or Black woman - BMI= 25-39 kg/m^2 (confirmed at baseline assessment) - At least one cardiometabolic risk factor: - < 150 minutes of self-reported moderate to vigorous exercise - History of gestational diabetes - Parent or sibling with prediabetes or diabetes - Personal or family history of hypertension (=130/80) - Prediabetes or impaired glucose metabolism (HgbA1c 5.7-6.5) - Personal or family history of abnormal cholesterol levels - At least 18 years of age - Able to read/speak English - Willing to attend scheduled classes, complete internet surveys and biomarker assessments - Able/willing to engage in moderate to vigorous exercise - Ambulatory - Superwoman Schema Questionnaire score indicating at least moderate endorsement of one or more subscales (strength: 7; motional suppression: 7; resistance of vulnerability: 8; motivation to succeed: 7; or helping others: 10) or a total score of 20 or greater - A Perceived Stress Scale-14 score of >5 or self-report at least "some" general stress. Exclusion Criteria: - Pregnant/anticipated pregnancy - Substance use, mental health or medical condition that will prevent the ability to participate in the intervention - Use of weight loss medication - Current or recent (<6 months prior to enrollment) engagement in another weight loss or meditation program - Impaired cognition (inability to follow and respond appropriately during screening). - Diabetes diagnosis - Has a confirmed BMI lower than 25 or higher than 39 - Does not have access to a smartphone or computer with internet access - Lives in the same household as someone who is currently in the study or was previously in the study. |
Country | Name | City | State |
---|---|---|---|
United States | The University of North Carolina at Chapel Hill | Chapel Hill | North Carolina |
Lead Sponsor | Collaborator |
---|---|
University of North Carolina, Chapel Hill | National Institute on Minority Health and Health Disparities (NIMHD) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Amount of Moderate to Vigorous Physical Activity | The participant's moderate to vigorous physical activity will be measured by triaxial accelerometry. Results will be reported in minutes, with higher numbers indicating a higher amount of moderate to vigorous physical activity. | Baseline, 48 weeks after first group session | |
Primary | Change in the Dietary Risk Assessment Score | The participant's dietary intake will be assessed using the dietary risk assessment, which includes 54 items. The dietary risk assessment measures the healthiness of a participant's eating habits. Score ranges from 0 to 108, with higher scores associated with less healthy dietary intake. | Baseline, 48 weeks after first group session | |
Primary | Change in Veggie Meter Score | The participant's nutrition will be assessed using the veggie meter, which uses light reflectance spectroscopy to provide an estimated skin carotenoid composite score. Score ranges from 0 to 800, with higher scores associated with greater fruit and vegetable intake. | Baseline, 48 weeks after first group session | |
Secondary | Change in BMI | The participant's BMI is calculated as weight (kg) divided by height (cm). | Baseline, 48 weeks after first group session | |
Secondary | Change in Weight | The participants weight will be measured using a digital scale. | Baseline, 48 weeks after first group session | |
Secondary | Change in Waist-to-Hip Ratio | The participant's waist to hip ratio is calculated by using the mean of two waist circumference measurements divided by mean of two hip circumference measurements. Waist circumference will be measured at the midpoint between the upper iliac crest and lower costal margin in the midaxillary line. Hip circumference will be measured at the maximum width of the buttocks or gluteo-femoral fold. | Baseline, 48 weeks after first group session | |
Secondary | Change in Percent Body Fat | The participant's percent body fat is measured using lange skinfold calipers. The final measurement will be the mean of three measurements on the right side of the body. | Baseline, 48 weeks after first group session | |
Secondary | Change in Blood Pressure (Systolic Blood Pressure/Diastolic Blood Pressure) | The participant's blood pressure is measured using an electronic sphygmomanometer. The final measurement will be the mean of three measurements. | Baseline, 48 weeks after first group session | |
Secondary | Change in High Sensitivity C-Reactive Protein Amount | The participant's high sensitivity C-reactive protein levels will be obtained via phlebotomy. C-Reactive Protein is an inflammatory biomarker, and indicative of cardiovascular risk. | Baseline, 48 weeks after first group session | |
Secondary | Change in IL-6 | The participant's IL-6 levels will be obtained via phlebotomy. IL-6 is an inflammatory biomarker, and indicative of cardiovascular risk. | Baseline, 48 weeks after first group session | |
Secondary | Change in Glycosylated Hemoglobin | Participant's glycosylated hemoglobin levels will be obtained via phlebotomy. Glycosylated hemoglobin amount is indicative of cardiovascular risk. | Baseline, 48 weeks after first group session |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |